Provider review
Fresh Day Meds review
Quotes a dose below the label start — then bills the "monthly" plan every 23 days.
The new-patient ladder names 0.22 / 0.44 / 0.88 mg, and 0.22 mg is genuinely under the label's own starting dose. The plan labeled monthly recurs 15.87 times a year.
Reviewed by Lena OrtizMetabolic Health Editor
Price updated August 2026
How we’re funded. Some links here are affiliate links: start care through one and we may earn a commission, at no extra cost to you. Affiliate partners are listed first on our rankings — what we write about a provider is the same either way, and unflattering findings about one that pays us stay in. Full disclosure.
Price as published
Fresh Day Meds
$140/mo at 0.22 mg (month-to-month)
- Vs median
- $29/mo below the $169 median
- Market
- $59–$1300/mo across 242 of 373
- Structure
- Quotes off the lowest dose
- Dispensed
- Compounded, 503A pharmacy
Advertising disclosure · we may earn a commission if you start care through some of these links, at no extra cost to you.
In one paragraph
The verdict
Two things here work in your favor if you are taking less. Its new-patient ladder names a milligram figure against every shipment rather than selling an unquantified starter tier, and the entry rung sits below the label's own starting dose for semaglutide, so the low rung is genuinely low rather than a standard start with a smaller price on it. It states 503A compounding and discloses that compounded medications are not FDA-approved — though it names no pharmacy, only the designation. Then there is the cadence, and it is the reason to read this row carefully. The plan it advertises as a one-month plan, with a renewal it describes as monthly, is set in its own checkout data to bill every 23 days. That is 15.87 charges a year rather than twelve, so the yearly cost runs about a third above what the advertised rate implies, and the interval appears nowhere in the plan's visible label. The quarterly plans do a smaller version of the same thing at 83 days rather than 91. Neither is a rounding artefact: both intervals are set explicitly, and both make the headline figure understate the real one.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
Who it suits, and who it does not
A good fit if
- You want the milligram figure attached to each shipment rather than inferred from a plan name
- You want an entry dose that is actually below the label's starting dose, not a relabeled standard start
- You want the dispensing pharmacy named before you order
- You are transferring an existing prescription, which gets its own cheaper track here
Look elsewhere if
- You are budgeting by the month — the plan called monthly bills every 23 days, so your annual cost is roughly a third higher than the rate suggests
- You are comparing headline rates across providers, because this one is not quoted on the same cadence as a calendar month
- You want the cheapest advertised figure without prepaying: that rate is a three-month plan charged upfront
- You want to know which pharmacy is dispensing — Fresh Day publishes the 503A designation but never the name
- You want published state coverage or a LegitScript identifier before ordering
What it actually costs
Price as published
Compounded semaglutide, month-to-month first because the cheaper figure is a prepay: "New to GLP-1 · 1-month plan" $140 at 0.22 mg, labeled "$140 monthly renewal" · the advertised "$99/mo" is the three-month plan at $299 charged upfront, covering shipments at 0.22 / 0.44 / 0.88 mg · transfer plans $140 monthly and $128/mo quarterly ($385) · the checkout data bills the one-month plans every 23 days and the quarterly plans every 83 days, not per calendar month or quarter
- Vs median
- $29/mo below the $169 median across the 242 of 373 programs we track that publish a plain monthly rate
- Market
- $59–$1300/mo is the full published spread in our ranking
- Structure
- Quotes off the lowest dose
States plainly that its advertised figures are based on the lowest dosage and that higher doses may cost more. On a general ranking that is a warning; for someone staying small it is the one model that bills accordingly.
36 of the 373 programs we track price a small dose this way. The row records a named milligram figure against each shipment of the new-patient ladder, with the entry rung at 0.22 mg — below the 0.25 mg/week label start — and the price rising with the dose. It is tiered on the DOSE BASIS, not on value: the row also records that the plan labeled monthly bills every 23 days, so the advertised rate understates the annual cost by roughly a third.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
What is included
- Consult
- Included in the price
- Dietitian
- Not included
- Labs
- Not required
- Pricing
- Varies by dose, plan or tier
- Price last updated
- August 2026
What it does well
- Publishes a milligram figure against each shipment of the new-patient plan — 0.22, 0.44 and 0.88 mg — instead of selling an unquantified starter tier
- The 0.22 mg entry dose is below the 0.25 mg/week label starting dose, so the low rung is genuinely low rather than a relabeled standard start
- Runs a separate, cheaper track for patients transferring an existing prescription, which most providers here do not distinguish
- The quarterly renewal figure is printed beside the monthly rate rather than only at checkout
Pharmacy, labs and oversight
Fresh Day Meds dispenses through a 503A facility. No bloodwork is required before you start. A clinician review is included in the price.
Transparency check
3 of 4 published openly
What Fresh Day Meds publishes about itself, read from its own pages when we verified them — not estimated, and not a score.
- Pharmacy named and regulatedDispensed by a 503A compounding pharmacy.
- Published
- A price you can read before intakeA monthly rate is published on its own pages — the figure in the price row above, read there and verified against it.
- Published
- What a higher dose costsPriced by dose, plan or tier, and the higher rungs are not published — the advertised figure does not tell you what a larger dose costs.
- Not published
- No FDA warning letter on fileChecked against the FDA's own warning-letter database; nothing on file for this company.
- None on file
How the program works
Fresh Day Meds is a direct-to-consumer telehealth service selling compounded semaglutide and tirzepatide, with separate plan tracks for patients new to GLP-1s and for patients transferring an existing prescription. It is unusual here in two ways. It quotes an explicit milligram figure against each rung of its new-patient ladder — 0.22, 0.44 and 0.88 mg across three monthly shipments — and the entry figure sits below the 0.25 mg/week that is the label's own starting dose for semaglutide. It states that its medication is prepared by a licensed 503A pharmacy and discloses that compounded medications are not FDA-approved, but it names no pharmacy anywhere anywhere on its public pages.
The honest cons
THE "1-MONTH PLAN" IS NOT MONTHLY. Its own checkout data sets the billing interval to 23 days, so a plan advertised at "$140/mo" with "$140 monthly renewal" recurs 15.87 times a year — about $2,222 annually against the $1,680 that twelve monthly charges would imply, roughly 32% more. The interval appears nowhere in the plan's visible label
- The quarterly plans bill every 83 days rather than every 91, so a "quarterly" renewal recurs 4.4 times a year, not 4
- The $99/mo headline is the three-month prepay rate at $299 charged upfront, not a month-to-month price — the real month-to-month figure is $140
- The advertised monthly rate and the actual billing cadence are published in different places, so a reader comparing headline prices across providers is not comparing like with like
- No compounding pharmacy is named. The site says only "503A licensed pharmacies" and, in its disclaimer, "state-licensed 503A and 503B compounding pharmacies" — a designation, not an identity, so a reader cannot check who is actually dispensing
- No LegitScript identifier or state coverage list is published anywhere on its public pages
- Compounded GLP-1s are not FDA-approved, and intentional microdosing is off-label and unproven
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
How it compares
Fresh Day Meds is one of 373 low-dose GLP-1 programs we track, and 242 of them publish a monthly rate you can read before signing up. The ranking lists every published price on one screen, ordered with the companies that pay us first — a mechanism we state there, on the page it applies to.
Where this sits
#77 of 373
Ordered with the companies that pay us first, and Fresh Day Meds is not one of them. A disclosed partition, not a score.
Compare all 373 providers →Read this before you buy
Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.
- What the evidence actually shows
- What microdosing GLP-1 costs
- Is compounded GLP-1 safe?
- The true annual cost of a plan
- Microdose & reconstitution calculator
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
The closest alternative
Elara MD
$249/mo at 0.2 mg/wk semaglutide
- Vs median
- $80/mo above the $169 median
- Market
- $59–$1300/mo across 242 of 373
- Structure
- Quotes off the lowest dose
- Dispensed
- Compounded, 503A pharmacy
Advertising disclosure · we may earn a commission if you start care through some of these links, at no extra cost to you.
Read the Elara MD review →Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.